p16(INK4A)/MTS1/CDKN2 - The melanoma gene? [p16(INK4A)/MTS1/CDKN2 das'melanomgen'? Stand der forschung und ausblick]

被引：0
|
作者：
Bogenrieder T. [1 ,2 ]
Landthaler M. [1 ]
Stolz W. [1 ]
机构：
[1] Dermatologische Klin. und Poliklin., Universität Regensburg, D-93053 Regensburg
来源：
Der Hautarzt | 1998年 / 49卷 / 2期
关键词：
CDK-inhibitors; Cell cycle; Malignant melanoma; p16(INK4A); Tumor-suppressor gen;
D O I：
10.1007/s001050050706
中图分类号：
学科分类号：
摘要：
The gene of the cyclin-dependent kinase 4 (CDK4)-inhibitor p16(INK4A) (CDKN2/MTS1) has been proposed as a candidate for a tumor-suppressor gene located on chromosome 9p21, a frequently deleted region in a series of human cancers including malignant melanoma. An increasing and sometimes conflicting body of data has accumulated regarding the frequency of homozygous deletions and mutations as well as the importance of p16(INK4A) in malignant melanoma. The purpose of this review is therefore to summarize the current knowledge on p16(INK4A) and to discuss its biologic significance in the pathogenesis of melanocytic tumors.
引用
收藏
页码：91 / 100
页数：9
相关论文
共 50 条
  • [21] Alterations of CDKN2(p16/MTS1) exon 2 in human hepatocellular carcinoma
    Qin, LX
    Tang, ZY
    Liu, KD
    Ye, SL
    He, B
    Zhang, Y
    Zhou, G
    [J]. ONCOLOGY REPORTS, 1996, 3 (02) : 405 - 408
  • [22] Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2 (p16(INK4A), MTS1) gene and other loci on human chromosome 9
    Wu, Q
    Possati, L
    Montesi, M
    Gualandi, F
    Rimessi, P
    Morelli, C
    Trabanelli, C
    BarbantiBrodano, G
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1996, 65 (06) : 840 - 846
  • [23] Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer
    Benedict, WF
    Lerner, SP
    Zhou, J
    Shen, XH
    Tokunaga, H
    Czerniak, B
    [J]. ONCOGENE, 1999, 18 (05) : 1197 - 1203
  • [24] High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma
    Reed, AL
    Califano, J
    Cairns, P
    Westra, WH
    Jones, RM
    Koch, W
    Ahrendt, S
    Eby, Y
    Sewell, D
    Nawroz, H
    Bartek, J
    Sidransky, D
    [J]. CANCER RESEARCH, 1996, 56 (16) : 3630 - 3633
  • [25] Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer
    William F Benedict
    Seth P Lerner
    Jain Zhou
    Xiaohua Shen
    Hideo Tokunaga
    Bogdan Czerniak
    [J]. Oncogene, 1999, 18 : 1197 - 1203
  • [26] p16 (CDKN2/MTS1) gene deletions are present in prostatic carcinoma in Japanese but not Americans
    Mangold, KA
    Takahashi, H
    Furusato, M
    Boyd, J
    Chandler, FW
    Allsbrook, WC
    [J]. LABORATORY INVESTIGATION, 1996, 74 (01) : 444 - 444
  • [27] CDKN2 (P16/MTS1) GENE DELETION OR CDK4 AMPLIFICATION OCCURS IN THE MAJORITY OF GLIOBLASTOMAS
    SCHMIDT, EE
    ICHIMURA, K
    REIFENBERGER, G
    COLLINS, VP
    [J]. CANCER RESEARCH, 1994, 54 (24) : 6321 - 6324
  • [28] Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme
    Hayashi, Y
    Ueki, K
    Waha, A
    Wiestler, OD
    Louis, DN
    vonDeimling, A
    [J]. BRAIN PATHOLOGY, 1997, 7 (03) : 871 - 875
  • [29] Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers
    Muzeau, F
    Flejou, JF
    Thomas, G
    Hamelin, R
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1997, 72 (01) : 27 - 30
  • [30] p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan
    Mangold, KA
    Takahashi, H
    Brandigi, C
    Wada, T
    Wakui, S
    Furusato, M
    Boyd, J
    Chandler, FW
    Allsbrook, WC
    [J]. JOURNAL OF UROLOGY, 1997, 157 (03): : 1117 - 1120
12345